



# Where Nature Ends, NurExone Begins

---

Transforming Regenerative Medicine

Q2 2025 | Canada (TSXV: NRX) Germany (FRA: J90.F) US (OTCQB: NRXBF)



# DISCLAIMER

Contents of this presentation are provided for general information purposes only and do not constitute an offer to sell or solicitation of an offer to buy any security in any jurisdiction.

This presentation contains “forward-looking information” for purposes of applicable securities laws (“forward-looking statements”). Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations or assumptions regarding the future of our business, future plans and strategies, our operational results and other future conditions. Forward-looking statements can be identified by words such as “anticipate”, “believe”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “seek”, “target”, “potential”, “will”, “would”, “could”, “should”, “continue”, “contemplate” and other similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements include all matters that are not historical facts. They appear in a number of places throughout this presentation and include statements regarding our intentions, beliefs or current expectations concerning, among other things, our financial performance, financial condition, liquidity, prospects, growth, strategies and the industry in which we operate. This forward-looking information includes, among other things, statements relating to: expectations regarding industry trends, overall market growth rates and our growth rates and growth strategies; our business plans and strategies; expectations regarding growth; our competitive position in our industry.

Although we base the forward-looking statements contained in this presentation on

assumptions that we believe are reasonable, we caution you that actual results and developments (including our financial performance, financial condition and liquidity, and the development of the industry in which we operate) may differ materially from those made in or suggested by the forward-looking statements contained in this presentation. Despite a careful process to prepare and review the forward-looking statements, there can be no assurance that the underlying opinions, estimates, and assumptions will prove to be correct. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future.

## **United States Securities Laws:**

This presentation does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities of NurExone Biologic Inc in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. The securities of NurExone Biologic Inc have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws and may not be offered or sold within the United States or to, or for the account or benefit of, "U.S. persons," as such term is defined in Regulation S under the U.S. Securities Act, unless an exemption from such registration is available.

NurExone does not declare and/or insure and/or imply on any specific result of any treatment which may be developed in the future based on the research and development process done or planned to be done by the Company.



*[Christopher] Reeve-Irvine Research Center (RIRC) :*

**“All scientists agree that the best way to restore function after spinal cord injury is to find ways to regenerate the [neural] connections that are broken ”<sup>1</sup>**

<https://www.reeve.uci.edu/research/regeneration-to-reverse-paralysis>


# COMPANY OVERVIEW

Founded in 2020, NurExone trades on the TSX Venture Canada (TSXV: NRX), Germany (FRA: J90.F) US (OTCQB: NRXBF)


## Key assets:

- **Technology:** 3 patent families and 2 exclusive worldwide licenses
- **Regulatory:** Orphan Drug Designation from FDA and EMA (EU)
- **Supply chain:** Exclusive Master Cell Bank for naïve exosome supply

SINCE ITS INCEPTION,  
NUREXONE HAS RAISED  
US\$~20M



# CORPORATE STRUCTURE



# ADDRESSING MULTI-BILLION DOLLAR GLOBAL MARKETS WITH UNMET MEDICAL NEEDS

## NurExone's first two Central Nervous System indications

### 1 Acute Spinal Cord Injury (SCI)



*“There is currently no way to repair a damaged or bruised spinal cord. But researchers are actively seeking ways to stimulate **spinal cord regeneration**”*<sup>1</sup>

There are an estimated 900K<sup>2</sup> new incidences of acute spinal cord injury globally each year. Using US figures, the lifetime direct care costs often exceed \$1M per patient<sup>3</sup> representing a multi-billion-dollar opportunity for **therapies that improve functional recovery and reduce long-term disability.**

1. <https://www.hopkinsmedicine.org/health/conditions-and-diseases/acute-spinal-cord-injury>

2. <https://pubmed.ncbi.nlm.nih.gov/35857624/>

3. <https://msktc.org/sites/default/files/Facts-and-Figures-2024-Eng-508.pdf>

### 2 Glaucoma - Acute Glaucoma



*“There is no cure (yet) for **glaucoma**”*<sup>4</sup>, Current treatments reduce eye pressure, postponing progression of the disease.

Acute glaucoma is a vision-threatening emergency affecting an estimated 350-700,000 people globally each year<sup>4</sup>. With the U.S. annual cost of blindness per patient at \$26,9K<sup>5</sup> this translates to a multi-billion dollar market **for therapies with potential of preserving or restoring vision in these patients.**

4. <https://pmc.ncbi.nlm.nih.gov/articles/PMC8841641/>



5. [https://www.aaojournal.org/article/S0161-6420\(21\)00710-7/fulltext](https://www.aaojournal.org/article/S0161-6420(21)00710-7/fulltext)

# ExoPTEN: Acute Spinal Cord Injury

## Preclinical Data Suggests Potential to Heal Damaged Neurons and Restore Motor Function


- Short cycles of NurExone's **regenerative ExoPTEN** therapy administered intranasally, led to **significant motor improvement, sensory recovery, and faster urinary reflex**
- **Functional recovery** accompanied by increased nerve regeneration, structural and electrophysiological improvements
- **Human trials, with minimally invasive administration, are expected to start in 2026\***

\*actual results may vary, see cautionary note on the company road map slide



# ExoPTEN: GLAUCOMA


Preclinical Data Suggests Optic Nerve Healing and Vision Restoration



ONC in one eye and was treated with ExoPTEN (green, ONC+PTEN), resulting in a retinal response similar to the healthy intact contralateral eye.

- Large scale preclinical study underway at Sheba Medical Center (ranked as the 8<sup>th</sup> best hospital globally in 2025 by Newsweek)

## Optic Nerve Cell Survival (Retinal Ganglion Cells)



A-left side-normal, B-middle-damaged, C-right side-after treatment,


- Minimally Invasive treatment showed functional restoration of damaged optic nerve to healthy levels in animals which lead to **75% functional recovery**.

*Optical Nerve Crush (ONC) - a Glaucoma animal model, mimic the Glaucoma nerve damage by causing-peruser damage and death of neurons at the optic nerve.*

# Pipeline

## Cutting Edge ExoTherapy Development to Recover Lost Function


A single process serving multiple high-value indications



# HOW DO WE DO IT? HARNESSING THE REGENERATIVE POWER OF EXOSOMES



Nature's "Guided Missiles" Targeting Inflammation

- Exosomes are naturally occurring nanoparticles with healing and "homing" capabilities
- We use MSC exosomes as "guided missiles" to deliver therapeutic cargo
- Exosomes can be loaded with a wide range of molecules to enhance their inherent therapeutic potential



# COMMERCIALIZATION: MULTI-LAYERED REVENUE STRATEGY

## Potential Revenue Streams

Product/Technology	Main Focus:
	<p><b>ExoPTEN</b> for Acute Spinal Cord Injury - leading product with accelerated “time to market” strategy</p> <p><b>ExoPTEN</b> for Optic Nerve Regeneration – leading product with high potential for out-licensing strategy</p>
	<p><b>Naïve exosomes</b> for</p> <ul style="list-style-type: none"><li>• B2B commercial applications</li><li>• Source for NurExone production</li></ul>
	<p>Licensing of ExoTherapy for drug delivery and other indications</p>

# PRODUCT ROAD MAP

## Clear Path towards Clinical Trials

### Plans for FDA and EMA approvals and a near term human clinical trial



**NurExone received Orphan Drug Designation (ODD) approval for its ExoPTEN for acute Spinal Cord Injury indication**

The information presented in this slide is forward-looking information which the Company does not commit or undertake to guarantee in any way. Investors should undertake their own risk assessment and analysis. The milestones shown are only an estimate and the actual development steps and/or results may differ from the estimated schedule presented here. The information is intended for illustrative purposes, its achievement is conditional on many factors over which the Company has no influence. The results of the R&D activities may impact the Company's achievements and schedules.



# EXPERIENCED LEADERSHIP TEAM



**Dr. Lior Shaltiel**  
Chief Executive Officer  
& Director

An entrepreneur and an award-winning scientist with extensive multidisciplinary international experience, specializing in chemical engineering, molecular biology, electrophysiology, pharmacology and drug delivery systems. Lior is the initiator and head of the BioMed-MBA program at the Hebrew University. Dr. Shaltiel holds B.Sc in Chemical engineering, BGUM.med.Sc in medical science (Physiology), and BGUPh.D - Pharmacology (LMU, Germany) Postdoctoral - Goethe University Frankfurt, Germany



**Mr. Eran Ovadya**  
Chief Financial Officer

A professional track record from 1st tier global corporations and significant expertise in public life-science and publicly-traded companies. Eran served for over a decade in a variety of finance roles for biotech companies including Gamida Cell, West pharma Israel, Omrix Biopharmaceuticals, a division of Ethicon Biosurgery, a Johnson & Johnson company, Macrocare, and Leap Therapeutics. Eran holds an MBA, specializing in financing, and a BA in accounting & economics from the Open University, Israel.



**Mr. Yoram Drucker**  
Founder, VP Strategic  
Development & Chairman

Successful Israeli entrepreneur and expert in the establishment of successful Stem cell start-ups. Founder and co-founder of several biotech companies, such as Pluristem, BrainStorm, InnoCan Pharma and others. served in C level management team and as a board member on private and public companies.



**Dr. Tali Kizhner**  
R&D Director

Over 15 years of R&D and CMC experience in therapeutic proteins and dietary supplements. Previously at Biond Biologics, she specialized in intracellular biologics delivery. As R&D Director at IFF, she led global initiatives in dietary supplements and functional foods. At Protalix Biotherapeutics, she contributed to developing FDA- and EMEA-approved biologics, including pegunigalsidase alfa for Fabry disease. Tali holds a Ph.D. in Biotechnology and Food Engineering from the Technion, with postdoctoral expertise in mesenchymal progenitor cells.



**Dr. Ina Sarel**  
Head of CMC,  
Quality and Regulation

A biotechnology executive with over 20 years of experience in product development from discovery and Proof of Concept through pre-clinical and clinical stages. Ina has broad expertise in stem/progenitor cell therapy, CMC, and regulatory requirements and previously developed a stem cell research product commercialized by Lonza. Ina holds a Ph.D. in Neuroendocrinology from Boston University, USA.

# SEASONED BOARD OF DIRECTORS



Israel



Canada



**Dr. Gadi Riesenfeld**

Director

Dr. Riesenfeld has served on the board of directors and as president of several bio pharmaceutical companies, including Kamapharm Ltd., Galisar Ltd., OticPharma and Pharmos Corporation, a publicly traded biotech company listed on NASDAQ



**Dr. Lior Shaltiel**

Chief Executive Officer

An entrepreneur and distinguished scientist with extensive international experience, specializing in chemical engineering, electrophysiology, pharmacology and drug delivery systems.



**Yoram Drucker**

Founder, VP Business Development & Active Chairman of the Board

Successful Israeli entrepreneur and expert in the establishment of successful Stem cell start-ups. Founder and co-founder of several biotech companies, such as Pluristem, BrainStorm, InnoCan Pharma and others. served in C level management team and as a board member on private and public companies.



**Oded Orgil, LL.B.**

Director

Mr. Orgil has over 25 years experience in Capital Markets as a Financial Advisor and Senior Executive for both bank owned and national Independent firms.. In his career on Bay Street Oded has participated in over \$10 Billion of capital market transitions and acquisitions.



**James (Jay) Richardson**

Director

Mr. Richardson has served as CEO or Chairman of several listed public companies and in others CFO and private company situations. He has extensive public company governance experience from over a dozen Board memberships including serving as Interim Chairman of the Argus Corporation.

# EXPERT SCIENTIFIC ADVISORY BOARD



## **Prof. Teodoro Forcht Dagi, MD, MPH**

neurosurgeon who serves as distinguished scholar and professor at Queen's University Belfast and the William J. Clinton Leadership Institute.



## **Prof. Gabriel Zeilig, MD**

Prof. Gabi Zeilig is the director of the Department of Neurological Rehabilitation and the National Spinal Cord Injury Rehabilitation Unit at the Sheba Medical Center, Tel Hashomer, Israel since 1999.



## **Prof. Michael Belkin, MD**

Prof. Belkin was the founder of the Eye Research Institute at the Sheba Medical Center who has been involved in the establishment of many medical start-ups.



## **Prof. Shulamit Levenberg, PhD**

Prof. Levenberg is the Dean of the Biomedical Engineering Department, Technion. Prof. Levenberg conducts interdisciplinary research on stem cells and tissue engineering



## **Yona Geffen, PhD, MSc**

nDr. Geffen advances CMC processes for preclinical and clinical activities at NurExone, focusing on developing analytical methods, qualifying potency assays, and optimizing dosing regimens.



## **Prof. Nahshon Knoller, MD**

Prof. Knoller established and headed the General Trauma at Sheba Medical Center. Dr. Knoller is a Director of the Spine Surgery Unit who treats and analyzes the entire range of spine and head pathologies.

# NUREXONE BIOLOGIC - SUMMARY

## Regenerating Nerves and Recovering Lost Function



ExoTherapy platform harnesses exosomes to deliver targeted therapies for a diverse range of diseases- a promising therapeutic approach with significant commercial potential.



Two clinical programs targeting areas with a high unmet need and large (\$1B+) commercial opportunities with near term milestones. A third indication is being explored as well.



Hybrid business model derisks opportunity with both inhouse development and licensing model for Exo-Therapy, providing potentially multiple revenue streams



Experienced management and advisory team outlines a clear development roadmap, supported by a robust intellectual property portfolio



**Exo-TOP (US) for naïve exosome production and sales, planned to generate revenue on H1 2026**

TSXV: NRX | TSXV: NRX | OTCQB: NRXBF

**THANK YOU**

For more information please contact:

[info@nurexone.com](mailto:info@nurexone.com)

#### DISCLOSURE

The matters discussed in this presentation are forward-looking statements that involve a number of risks and uncertainties. The actual future results of the company could differ significantly from those statements. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements. This document does not constitute an offer to sell or a solicitation of offers to buy any securities of the company or any entity.